FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded approval of Moderna's RSV vaccine, mResvia, to include adults aged 18-59 at high risk, a positive development after recent setbacks including the cancellation of $760M in HHS grants due to unsubstantiated safety concerns regarding mRNA vaccines; however, a CDC panel's recommendation for use in the 50-59 age group, necessary for insurance coverage, is currently stalled due to inaction from the Health and Human Services Department.

Analysis

The Food and Drug Administration's decision to expand the approval of Moderna's RSV vaccine, mResvia, to include high-risk adults aged 18 to 59 represents a notable regulatory milestone, potentially broadening the vaccine's addressable market beyond its previous license for adults 60 and older. Moderna CEO Stéphane Bancel highlighted this as an important step in protecting additional populations. However, this positive development is set against a backdrop of significant challenges for the company, including what the article describes as "deep distrust" of its mRNA platform, particularly among supporters of Health Secretary Robert F. Kennedy Jr., and recent social media criticism following the approval of its restricted-use second-generation Covid-19 vaccine, mNexspike. A critical uncertainty impacting mResvia's commercial prospects in the newly approved demographic is the status of a recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP). While ACIP voted in April to recommend RSV vaccine use for medically at-risk adults aged 50-59—a recommendation structured to include Moderna's vaccine post-FDA approval—this endorsement requires approval from either the CDC Director or the HHS Secretary to ensure insurance coverage. With no current CDC Director and HHS Secretary Kennedy not having signed off in nearly two months (despite approving other ACIP recommendations), the mResvia recommendation remains in limbo, meaning insurers are not obligated to cover its cost for this younger cohort. This situation is further complicated by Kennedy's recent dismissal of the entire ACIP and appointment of new members, alongside a major financial blow where HHS canceled over $760 million in grants to Moderna for mRNA flu vaccine development due to "unsubstantiated concerns" about mRNA vaccine safety. Despite these headwinds, Moderna plans to have mRESVIA available for both the 18-59 high-risk group and adults 60+ for the 2025-2026 season, though the overall sentiment for MRNA remains moderately negative (-0.8) reflecting these substantial uncertainties.

Key Decisions for Investors

• Investors should view the expanded FDA approval for mResvia cautiously, as its commercial success in the 18-59 high-risk demographic is heavily contingent on securing a favorable ACIP recommendation and subsequent HHS approval to ensure insurance reimbursement, which is currently stalled.
• The cancellation of over $760 million in HHS grants and the ongoing scrutiny of mRNA technology by HHS Secretary Kennedy, including the recent overhaul of the ACIP, signal heightened regulatory and political risks for Moderna that could impact future product approvals, funding, and market adoption.
• Monitor closely the upcoming late June ACIP meeting with newly appointed members and any subsequent actions by HHS Secretary Kennedy regarding the mResvia recommendation, as these events will be critical determinants for the vaccine's uptake and revenue potential in the expanded age group.